Research
Hormonal
GLP-1RAs may have little or no effect on pancreatic cancer risk.
Practitioners should be aware that GLP-1RAs may not significantly increase pancreatic cancer risk.
StrongQualifiesmedium confidence
GLP-1RAs may have little or no effect on pancreatic cancer (OR, 0.84 [CI, 0.53 to 1.35]; 9 fewer to 6 more per 10 000).
Why this rating
Based on a meta-analysis of randomized placebo-controlled trials.
Source
Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists
Albert Ko et al. · Annals of Internal Medicine · 2025
DOI 10.7326/annals-25-02237
Meta-analysisCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →